Objective  To evaluate the efficacy and safety of liraglutide combined with acarbose in the treatment of obese type 2 diabetes mellitus by Meta-analysis.

Methods   A comprehensive computerized search of the China Biomedical Literature Database (CBM), China Knowledge Internet (CNKI), Wanfang Database, Chinese Science and Technology Journal Database (VIP), PubMed, Embase, The Cochrane Library, and Web of Science was conducted to collect data on the use of liraglutide in combination with acarbose for the treatment of obesity type 2 diabetes mellitus compared with the use of acarbose alone. Randomized controlled trials (RCTs) comparing treatment of obese type 2 diabetes. Meta-analysis was performed using RevMan 5.3 software, with relative risk ratio (RR) as the effect size for dichotomous data and mean difference (MD) as the effect size for continuous data.

Results  A total of 14 RCTs containing 1,416 patients were included, including 709 in the liraglutide combined with acarbose group and 707 in the acarbose alone group. The results showed that the difference between the liraglutide combined with acarbose group and single acarbose treatment was statistically significant in reducing fasting glucose, 2 h postprandial glucose, body mass index, total cholesterol, triglycerides, glycosylated hemoglobin, and insulin resistance index (P<0.05); and there was no statistically significant difference in the incidence of hypoglycemia and the incidence of gastrointestinal system adverse reactions between the two groups (P>0.05).

Conclusion  Liraglutide combined with acarbose in the treatment of obese type 2 diabetes mellitus is superior to the single use of acarbose in lowering fasting glucose, postprandial 2h glucose, body mass index, total cholesterol, triglyceride, glycosylated hemoglobin, and insulin resistance index, and does not increase the incidence of hypoglycemia and digestive system adverse reactions.

1.Javeed N, Matveyenko AV. Circadian etiology of type 2 diabetes mellitus[J]. Physiology (Bethesda), 2018, 33(2): 138-150. DOI: 10.1152/physiol.00003.2018.

2.Al Mamun A, Ara Mimi A, Wu Y, et al. Pyroptosis in diabetic nephropathy[J]. Clin Chim Acta, 2021, 523: 131-143. DOI: 10.1016/j.cca.2021.09.003.

3.Gale MJ, Scruggs BA, Flaxel CJ. Diabetic eye disease: a review of screening and management recommendations[J]. Clin Exp Ophthalmol, 2021, 49(2): 128-145. DOI: 10.1111/ceo.13894.

4.Faselis C, Katsimardou A, Imprialos K, et al. Microvascular complications of type 2 diabetes  mellitus[J]. Curr Vasc Pharmacol, 2020, 18(2): 117-124. DOI: 10.2174/1570161117103733.

5.Pitocco D, Spanu T, Di Leo M, et al. Diabetic foot infections: a comprehensive overview[J]. Eur Rev Med Pharmacol Sci, 2019, 23(2): 26-37. DOI: 10.26355/eurrev_201904_17471.

6.Ng SC, Xu Z, Mak J, et al. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial[J]. Gut, 2022, 71(4): 716-723. DOI: 10.1136/gutjnl-2020-323617.

7.侯睿. 我国代谢手术缓解肥胖2型糖尿病的研究概况[J]. 中国临床医生杂志, 2022, 50(7): 789-793. [Hou R. An overview of our research on metabolic surgery to alleviate obese type 2 diabetes mellitus[J]. Chinese Journal of Clinical Physicians, 2022, 50(7): 789-793.] DOI: 10.3969/j.issn.2095-8552.2022.07.010.

8.张宇, 王鹏源, 刘霞. 肥胖2型糖尿病药物研究进展 [J]. 药学实践杂志, 2019, 37(2): 97-102. [Zhang Y, Wang PY, Liu X. Research progress on obesity type 2 diabetes mellitus drug[J]. Journal of Pharmaceutical Practice, 2019, 37(2): 97-102.] DOI: 10.3969/1.issn 1006-0111.2019.02.001.

9.黄会, 高庆伟, 刘晓波, 等. 瑞格列奈联合阿卡波糖治疗2型糖尿病疗效和安全性的Meta分析[J]. 中国药物评价, 2022, 39(3): 254-260. [Huang H, Gao QW, Liu XB, et al. Meta-analysis of the efficacy and safety of repaglinide combined with acarbose in the treatment of type 2 diabetes mellitus[J]. Chinese Journal of Drug Evaluation, 2022, 39(3): 254-260.] DOI: 2095-3593(2022)03-0254-07.

10.Drugs for type 2 diabetes[J]. Med Lett Drugs Ther, 2019, 61(1584): 169-178. https://pubmed.ncbi.nlm.nih.gov/31770362/.

11.付宇, 裴斌, 艾金伟, 等. 臭氧联合糖皮质激素治疗肩周炎有效性的Meta分析[J]. 湖北医药学院学报, 2016, 35(1): 52-57. [Fu Y, Pei B, Ai JW, et al. The effectiveness of ozone combined with glucocorticoid for therapy frozen shoulder: a Meta - analysis[J]. Journal of Hubei University of Medicine, 2016, 35(1): 52-57.] DOI: 10.13819/j.issn.1006-9674.2016.01.013.

12.刘亚旭, 郭伟亭. 利拉鲁肽联合阿卡波糖治疗肥胖2型糖尿病观察[J]. 实用中西医结合临床, 2022, 22(7): 61-63. [Liu YX, Guo WT. Liraglutide combined with acarbose in the treatment of obese type 2 diabetes mellitus[J]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine, 2022, 22(7): 61-63.] DOI: 10.13638/j.issn.1671-4040.2022.07.017.

13.陈丹. 利拉鲁肽联合阿卡波糖治疗肥胖2型糖尿病患者的效果[J]. 中国民康医学, 2021, 33(3): 26-28. [Chen D. Effect of liraglutide combined with acarbose in the treatment of obese patients with type 2 diabetes mellitus[J]. Chinese National Health Medicine, 2021, 33(3): 26-28.] DOI: 10.3969/j.issn.1672-0369.2021.03.011.

14.樊姨君, 靳明伟. 利拉鲁肽联合阿卡波糖治疗肥胖2型糖尿病的效果及对体质量指数的影响[J]. 首都食品与医药, 2020, 27(21): 59. [Fan YJ, Jin MW. Effect of liraglutide combined with acarbose in the treatment of obese type 2 diabetes mellitus and its effect on body mass index[J]. Capital Food and Medicine, 2020, 27(21): 59.] DOI: 1005-8257(2019)04-0064-01.

15.高强. 利拉鲁肽联合阿卡波糖治疗肥胖2型糖尿病患者临床疗效观察[J]. 糖尿病新世界, 2020, 23(7): 53-54. [Gao Q. Clinical efficacy of liraglutide combined with acarbose in the treatment of obese patients with type 2 diabetes mellitus[J]. Diabetes New World, 2020, 23(7): 53-54.] DOI: 10.16658/j.cnki.1672-4062.2020.07.053.

16.沈翔. 利拉鲁肽联合阿卡波糖治疗肥胖2 型糖尿 病临床疗效分析[J]. 健康之友, 2020, (8): 277. [Shen  X. Clinical efficacy analysis of liraglutide combined with acarbose in the treatment of obese type 2 diabetes mellitus[J]. Healthy Friends, 2020, (8): 277.] DOI: 1002-8714(2020)04-0277-01.

17.韩志敬. 利拉鲁肽联合阿卡波糖治疗肥胖2型糖尿病临床疗效观察[J]. 医学理论与实践, 2020, 33(6): 914-915. [Han ZJ. Clinical efficacy of liraglutide combined with acarbose in the treatment of obese type 2 diabetes mellitus[J]. Medical Theory and Practice, 2020, 33(6): 914-915.] DOI: 10.19381/j.issn.1001-7585.2020.06.024.

18.仲小莉, 郭雨淋. 利拉鲁肽联合阿卡波糖对肥胖2型糖尿病患者血糖控制及体质量指数的影响分析 [J]. 首都食品与医药, 2019, (8): 64. [Zhong XL, Guo YL. Analysis of the effect of liraglutide combined with acarbose on glycemic control and body mass index in obese type 2 diabetes mellitus patients[J]. Capital Food and Medicine, 2019, (8): 64.] DOI: 10.3969/j.issn.1005-8257.2019.08.050.

19.杨丽. 利拉鲁肽联合阿卡波糖治疗肥胖2型糖尿病患者临床疗效观察[J]. 全科口腔医学电子杂志, 2019, 6(29): 184-187. [Yang L. Clinical efficacy observation of liraglutide combined with acarbose in the treatment of obese type 2 diabetes mellitus patients[J]. Electronic Journal of General Practice Dentistry, 2019, 6(29): 184-187.] DOI: 10.16269/j.cnki.cn11-9337/r.2019.29.151.

20.宋秋萍, 胡淼. GLP-1类似物联合阿卡波糖对肥胖2型糖尿病患者血清Chemerin,Visfatin HbA1c水平的影响[J]. 中国医师杂志, 2018, 20(12): 1858-1860. [Song QP, Hu M. Effect of GLP-1 analog combined with acarbose on serum Chemerin and Visfatin HbA1c levels in obese type 2 diabetic patients[J]. Chinese Journal of Physicians, 2018, 20(12): 1858-1860.] DOI: 10.3760/cma.j.issn.1008-1372.2018.12.028.

21.史桃芬, 周晓芳. 利拉鲁肽联合阿卡波糖对肥胖2型糖尿病患者血糖控制及体重指数的影响[J]. 糖尿病天地, 2018, 15(6): 91-92. [Shi TF, Zhou XF. Effect of liraglutide combined with acarbose on glycemic control and body mass index in obese type 2 diabetes mellitus patients[J]. Diabetes World, 2018, 15(6): 91-92.] DOI: 1005-8257(2019)04-0064-01.

22.林杰. 利拉鲁肽联合阿卡波糖治疗肥胖2型糖尿病患者应用效果评价[J]. 临床医药文献电子杂志, 2018, 5(82): 61-64. [Lin J. Evaluation of the application effect of liraglutide combined with acarbose in the treatment of obese type 2 diabetes mellitus patients[J]. Electronic Journal of Clinical Medicine Literature, 2018, 5(82): 61-64.] DOI: 10.16281/j.cnki.jocml.2018.82.040.

23.韩伟, 刘德宽, 张俊岭. 利拉鲁肽联合阿卡波糖治疗肥胖2型糖尿病患者临床疗效观察[J]. 内科, 2017, 12(3): 319-322. [Huan W, Liu DK, Zhang JL. The clinical curative effect of liraglutide combined with acarbose in the treatment of patients with obesity type 2 diabetes[J]. Internal Medicine, 2017, 12(3): 319-322.] DOI: 10.16121/j.cnki.cn45-1347/r.2017.03.07.

24.杨利和. 利拉鲁肽联合阿卡波糖治疗2型糖尿病的临床疗效[J]. 临床医药实践, 2015, 24(11): 865-867. [Yang LH. Clinical efficacy of liraglutide combined with acarbose in the treatment of type 2 diabetes mellitus[J]. Clinical Medicine Practice, 2015, 24(11): 865-867.] DOI: 10.16047/j.cnki.cn14-1300/r.2015.11.029.

25.李兴福. 利拉鲁肽联合阿卡波糖治疗肥胖型2型糖尿病临床疗效观察[J]. 医学综述, 2014, 20(11): 2093-2095. [Li XF. Clinical efficacy observation of liraglutide combined with acarbose in the treatment of obese type 2 diabetes mellitus[J]. Medical Review, 2014, 20(11): 2093-2095.] DOI: 10.3969 /j. issn.1006-2084.2014.11.073.

26.Al-Sulaiti H, Diboun I, Agha MV, et al. Metabolic signature of obesity-associated insulin resistance and type 2 diabetes[J]. J Transl Med, 2019, 17(1): 348. DOI: 10.1186/s12967-019-2096-8.

27.翟所迪, 陈忻. 利拉鲁肽临床安全性分析[J]. 中国医院药学杂志, 2012, 32(7): 546-548. [Zhai SD, Chen X. Clinical safety analysis of liraglutide[J]. Chinese Journal of Hospital Pharmacy, 2012, 32(7): 546-548.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2012.07.029.